The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
JEEN’s portfolio includes a diverse range of specialized active ingredients, botanical extracts, and complexes serving functional applications for skin and hair care
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Subscribe To Our Newsletter & Stay Updated
